Abstract: Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said surface to form a solid covering on said surface, followed by removing said solid covering from the wound. The alginate composition adheres strongly to bacterial biofilms on the wound, whereby the biofilms are removed with the alginate composition. The moulding composition may be used in conjunction with a staining agent that undergoes a colour change in the presence of bacteria or bacterial polysaccharides to show the presence and removal of the biofilm. Also provided are methods of treating wounds using the compositions.

Abstract: The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.

Abstract: Short single chain peptides having affinity for a target surface often lack the binding durability required for certain commercial applications. One way to improve durability is to promote multivalent binding by linking together binding sequences using peptide linkers. However, the resulting single chain binding peptides often suffer from linker entropy. It has been discovered that the use of rigid peptide linkers when linking together multiple binding sequences enhances the binding affinity of the resulting single chain peptide.

Abstract: The present invention relates to a composition, for inhibiting dental erosion, and the use thereof. The composition comprises an aqueous solution of hydrofluoric acid, in which the concentration of hydrofluoric acid is 0.05%-2.00% and the pH is between 2.5 and 4.5.

Abstract: The invention provides novel dental film-forming compositions, comprising i. an acrylate/octylacrylamide copolymer, ii. one or more alkyl cellulose ethers, and iii. a solvent, and optionally further comprising whitening materials and/or active agents, together with method for using the same.

Abstract: A mouthwash composition comprises water and a modified polyglutamic acid composed of a plurality of segment A and a plurality of segment B randomly arranged, in which, the segment A has a formula I: The segment B has a formula II: wherein X?H, Na, K, NH4, ½Ca, or ½Mg, and Y?Cl, Br, or I. The modified polyglutamic acid in the mouthwash composition is 0.1-5 wt %. The mouthwash composition in the present invention can eliminate bad breath, and also has antibacterial properties, so it can suppress the formation of dental plaque and is effective in preventing periodontal disease.

Abstract: The present invention relates to oral compositions, comprising select polyethylene oxide-polypropylene oxide block copolymer surfactants. Methods for using the compositions are also disclosed.

Abstract: The present invention relates to oral compositions, comprising select polyethylene oxide-polypropylene oxide block copolymer surfactants. Methods for using the compositions are also disclosed.

Abstract: The present invention relates to method for treating or preventing tooth decay, gum disease or sensitive teeth and to compositions, devices and kits for use in this method. The method comprises the application of an oral care composition to the gum and teeth of an individual using an applicator. In the method, there is a contact time between the oral care composition and the gum and teeth of at least 5 minutes. The applicator is preferably removed directly after application of the oral composition.

Abstract: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 13.9. The composition has a volume fraction of oil portion relative to the sum of the oil portion plus C2 or C3 mono alcohol that is greater than 0.091.

Abstract: The invention relates to a preparation and to a method for inducing, enhancing or accelerating the skin pigmentation, both for mere cosmetic purposes and for therapeutic purposes, for the therapy and/or prophylaxis of dischromic pathologies of the skin. The method is based on the application of a topical skin preparation containing NGF (Nerve Growth Factor), so as to obtain an intensification of the skin color or the re-pigmentation of de-pigmented epidermal areas following vitiligo or other hypopigmentary skin diseases. The preparation of NGF and the connected method can also be used in combination with other therapies known for the treatment of skin discoloration, such as the application of topical corticosteroids, activated vitamin D and/or activated vitamin D3, or phototherapy alone or in combination with photosensitizing agents, in particular psoralens.

Abstract: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 45, where the composition has a volume fraction of oil relative to oil plus C2 or C3 mono-alcohol that is about 0.47 or greater, and is substantially free of a mixture of a low-volatility, C2-C8 liquid silicone and a branched fatty acid ester of a polyprotic carboxylic acid in a ratio of from about 3:1 to 4.25:1.

Abstract: The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting inflammatory activity in skin tissue of a mammal, for protecting skin tissue of a mammal from ultraviolet light-induced damage, and for normalizing skin disorders in skin tissue of a mammal. The present invention also relates to methods for isolating bioactive fractions derived from cell juice or a cell walls component a Theacea plant.

Abstract: A method for increasing and/or synchronizing per1 gene expression in skin cells having decreased, irregular, or asynchronous per1 gene expression comprising treating the skin cells with an effective amount of cichoric acid, and the resulting compositions.

Abstract: A nail coating composition having a reduced exotherm during actinic curing of the coating on a nail. The composition may include a curable resin, a monomer, a photoinitiator, a chemical filter capable of absorbing ultraviolet (UV) light and reducing exotherm, and an additive.

Abstract: The present invention is directed to the prophylatic field treatment of photodamaged skin with topical ingenol mebutate. More specifically, the present invention concerns field-directed treatment of UV-damaged skin with topical ingenol mebutate for reducing the number of skin lesions that emerge from the UV-damaged skin over time. In addition, the present invention concerns field-directed treatment for removing photodamaged skin, mutated keratinocytes, cutaneous immunosuppressive environments and/or p53+ patches caused by UV with topical ingenol mebutate. By way of example, the present invention is directed to treating photodamaged skin with topical ingenol mebutate at about 0.05% concentration. The present invention is also concerned with the treatment of SCC tumors with topical ingenol mebutate for reducing the number of SCC tumors. By example, the present invention is directed to treating and curing SCC xenografts with topical ingenol mebutate at about 0.25% concentration.

Abstract: This invention provides a Chinese medicinal formula comprising Atractylodis Macrocephalae Rhizoma, Glycyrrhizae Radix et Rhizoma, Angelicae sinensis Radix, Paeoniae Radix Alba and Poria for skin care. It further relates to a method for preparing bioactive fraction of this formula and to the applications of the bioactive fraction in skin-whitening and anti-skin-aging.

Abstract: The invention relates to a composition, especially a cosmetic composition, comprising at least one ester of polyol(s) and of fatty diacid dimer or an ester thereof, at least one acrylic film forming agent and at least one tackifier, as well as to methods of using such compositions.

Abstract: Antiperspirant/deodorant compositions have lower, or even zero amounts of aluminium and/or zirconium antiperspirant actives. A polymer having one or more anhydride and/or diacid moieties, such as succinic (maleic) anhydride and/or diacid. The antiperspirant/deodorant compositions comprise a polymer with a non-zero acid value and a cationic species, which may be a cationic polymer, cationic molecule, cation, and/or a cationic carrier. Product are formed for the antiperspirant/deodorant composition, as well as a method of treating perspiration.

Abstract: The present invention relates to non-aqueous emulsions stabilised by silica particles and to processes for making them. The invention further comprises: a particle stabilized oil-in-polar (o/polar o/p) emulsion comprising: a) a dispersed oil phase, b) a continuous polar phase substantially free of water, c) a particulate solid which is a silica particle dispersant possessing surface silanol groups (SiOH) sufficient to stabilize the emulsion, and where the emulsion is substantially free of emulsifiers, surfactants; and wherein the oil phase (a) is dispersed as discontinuous droplets in the polar phase (b); the silica particle dispersant (c) is absorbed on the surface of the oil phase (a); and the silica particle dispersant (c) is partially wetted by the polar phase (b).

Abstract: The present invention relates to a new cosmetic product for treating keratinous materials, particularly hair, to the method for preparing the cosmetic product, and to a cosmetic method for the care of keratinous material using these compositions.

Abstract: Compositions and methods for of their use in treating human or other mammalian skin and hair. Non-ionic, salt-free non-solidifying formulations of Lauroyl N methyl-C10, C12, C14, C16 alkanoyl-N-methyl-glucamide and alkyl glycosides are disclosed that impart beneficial barrier properties to skin and hair.

Abstract: There is provided a new use of a hydroxydihydrobovolide compound having effects on preventing hair loss and growing hairs. Since the hydroxydihydrobovolide compound has effects on increasing survival rates of human hair follicle dermal papilla cells and hair outer root sheath cells and also growing a length of hairs, the compound is of great value as a pharmaceutical composition or cosmetic composition for improving scalp or preventing hair loss. Further, since the hydroxydihydrobovolide compound is isolated and purified from Eucheuma cottonii that is red algae and does not induce cytotoxicity, it is stable in the body and thus can be used as a raw material for functional health food.

Abstract: Suggested is a ginger extract, comprising (a) 25 to 30% b.w. [6]-gingerol (b) 5 to 10% b.w. [8]-gingerol (c) 5 to 10% b.w. [10]-gingerol (d) 1.5 to 4% b.w. [6]-shogaol (e) 0.3 to 1.3% b.w. [8]-shogaol; (f) 0.03 to 1% b.w. [10]-shogaol; (g) 0.01 to 1% b.w. zingerone, on condition that the amount of gingerols sums up to 35 to 50% b.w. and the amount of shogaols sums up to 1.5 to 6% b.w.

Abstract: Generally, compositions which can be applied to hair, fur or skin of an animal and are useful for reducing, removing or eliminating undesirable materials or odors or parasites (“extraneous matter”) from the hair, fur or skin of the animal. Specifically, compositions which can be applied to hair, fur or skin of an animal and can reduce, remove or eliminate undesirable materials or odors or parasites (“extraneous matter”) from the hair, fur or skin of the animal without a need of a rinse composition.

Abstract: The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

Abstract: The present invention relates generally to topical compositions and methods of using the same.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.

Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that is co-infected with HIV.

Abstract: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen atom or a hydroxyalkyl group. The peroxide derivative exhibits potent anti-HCV activity by remarkably suppressing HCV-RNA replication.

Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.

Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.

Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Abstract: The present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms.

Abstract: Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.

Abstract: The invention relates to transgene expression constructs—particularly self inactivating lentiviral vectors—comprising a dendritic cell specific promoter controlling the expression of autoantigen proteins, namely myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, for use in the therapy of multiple sclerosis.

Abstract: The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells.

Abstract: A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.

Abstract: The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. The invention is further directed to reducing inflammation of the paranasal sinuses.

Abstract: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for treating hemorrhoids. The invention is also directed to methods for preventing hemorrhoids. The invention is further directed to reducing inflammation associated with hemorrhoids. The invention is further directed to methods for preventing hemorrhoids and/or treating hemorrhoids and/or reducing inflammation associated with hemorrhoids by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions.

Abstract: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive factor, for example biocompatible ceramics and glass.

Abstract: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Abstract: Methods and compositions are provided for the production of stem cells and induced pluripotent stem cells, and for uses thereof.